Bernardo Maria Ester Professore AssociatoMedicinaMed/38

Biografia

Pubblicazioni

Biografia

ISTRUZIONE & FORMAZIONE

Marzo 2010: discussione della tesi di Dottorato (PhD) presso l’Università di Leiden, Olanda; titolo della tesi: “Human mesenchymal stem cells: biological characterization and clinical application” sotto la supervisione del Prof. W.E. Fibbe.

30 Ottobre 2005: specializzazione in Pediatria presso l’Università di Pavia; titolo della tesi: “Studio del potere condrogenico delle cellule stromali mesenchimali isolate da differenti sorgenti tissutali”; votazione finale: 50/50 cum laude.

Aprile 2001: Esame di Stato per l’abilitazione alla professione di Medico Chirurgo.

20 luglio 2000: Laurea in Medicina e Chirurgia, Università di Pavia, titolo della tesi: “Ricostituzione immunologica dopo trapianto di cellule staminali cordonali”; votazione finale: 110/110 cum laude.

ATTIVITA’ DIDATTICA

Dall’1 luglio 2020 a tutt’oggi: Professore Associato in Pediatria, Università Vita-salute San Raffaele, Milano.

Da settembre 2015 a tutt’oggi: Professore a Contratto (totale di 10 ore di lezione) per il corso di Paediatrics, International Medical Doctor Program, Università Vita-Salute San Raffaele, Milano.

Membro del Collegio Docenti, Scuola di Specialità in Pediatria, Università Vita-Salute San Raffaele, Milano.

Membro del Comitato Direttivo del Corso di dottorato “PhD Program in Molecular Medicine” dell’Università Vita-Salute San Raffaele e Vice-Direttore del CurriculumCell and Gene Therapy” del PhD Program in Molecular Medicine, UniversitàVita-Salute San Raffaele, Milano.

Contro-relatore di 2 tesi del Corso di dottorato “PhD Program of Translational and Molecular Medicine (DIMET)”, Università degli Studi di Milano Bicocca.

Revisore di N. 4 tesi del Corso di Dottorato “Medicina dello sviluppo e scienze della Programmazione Sanitaria”, Università of Padova.

Co-relatore di una tesi di Laurea del Corso di Medicina e Chirurgia, Università Vita-Salute San Raffaele e di una tesi di Laurea del Corso di Ricerca Biotecnologica in Medicina, Università Vita-Salute San Raffaele. Contro-relatore di 2 tesi di Laurea del Corso di Ricerca Biotecnologica in Medicina, Università Vita-Salute San Raffaele, Milano.

Supervisore in qualità di tutor di N. 4 Specializzandi in Pediatria, Università Vita-Salute San Raffaele, Milano.

Dal 2015 a tutt’oggi effettua lezioni frontali per gli Specializzandi in Pediatria, Università Vita-Salute San Raffaele, Milano.

Dal 2017 a tutt’oggi effettua lezioni frontali al Corso di dottorato “PhD Program of Translational and Molecular Medicine (DIMET)”, Università degli Studi di Milano Bicocca.

Febbraio 2014: Abilitazione Scientifica Nazionale a Professore Universitario di II fascia in Pediatria

ATTIVITA’ CLINICO-ASSISTENZIALE

Da ottobre 2016 a tutt’oggi: Responsabile Unità Funzionale (RUF), Unità di Immuno-ematologia Pediatrica, IRCCS Ospedale San Raffaele, Milano.

Da dicembre 2014 a tutt’oggi: Coordinatore Area Trapianto Allogenico Pediatrico, Unità di Immuno-ematologia Pediatrica, IRCCS Ospedale San Raffaele, Milano.

Da novembre 2014 a tutt’oggi: Pediatra assunta a tempo indeterminato, Unità di Immuno-ematologia Pediatrica, IRCCS Ospedale San Raffaele, Milano.

Da luglio 2020 a tutt’oggi: Principal Investigator del protocollo clinico ‘A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human a-L-iduronidase gene for the treatment of patients affected by Mucopolysaccharidosis Type I, Hurler variant’ attualmente in corso presso l’Unità di Immuno-ematologia Pediatrica, IRCCS Ospedale San Raffaele, Milano (data di approvazione dello studio: 10 maggio 2018).

Da maggio 2018 a giugno 2020: Co-Principal Investigator del protocollo clinico ‘A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human a-L-iduronidase gene for the treatment of patients affected by Mucopolysaccharidosis Type I, Hurler variant’ attualmente in corso presso l’Unità di Immuno-ematologia Pediatrica, IRCCS Ospedale San Raffaele, Milano.

Maggio 2010 - novembre 2014: Pediatra assunta a tempo indeterminato, Dipartimento di Ematologia ed Oncologia, IRCCS Ospedale Pediatrico Bambino Gesù, Roma.

Aprile 2009 - maggio 2010: Pediatra assunta a tempo indeterminato, Dipartimento di Onco-ematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia

Aprile 2007 - luglio 2009: Pediatra assunta a tempo determinato, Dipartimento di Onco-ematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia

Novembre 2005 - marzo 2007: Contratto di ricerca - Dipartimento di Onco-ematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia.

Presso l’Unità di Immuno-ematologia Pediatrica, IRCCS Ospedale San Raffaele e l’Istituto San Raffaele Telethon per la Terapia Genica svolgo sia attività clinica sia di ricerca pre-clinica. Ciò mi consente di rivestire un ruolo unico di medico traslazionale grazie all’ampia e solida esperienza clinica nell’ambito trapianto di cellule staminali emopoietiche, associata alle competenze di ricerca di base maturate con il Dottorato di ricerca all’estero e le successive attività di laboratorio. Presso il nostro Istituto ho sviluppato, come Co-PI , uno studio “first-in-human” basato sull’utilizzo della terapia genica ex-vivo con cellule staminali emopoietiche ingegnerizzate con un vettore lentivirale per i bambini affetti dalla Mucopolisaccaridosi di tipo I, variante Hurler. Nell’ambito di questo protocollo, oltre a seguire il trattamento dei pazienti sottoposti a terapia genica, mi occupo di sviluppare alcune linee di ricerca per comprendere al meglio sia i meccanismi patogenetici della malattia sia i meccanismi di correzione attraverso la terapia genica.

ATTIVITA’ SCIENTIFICA & DI RICERCA

Da novembre 2017 a tutt’oggi: Coordinatore Clinico, Unità di Ricerca Clinica Pediatrica, San Raffaele Telethon-Institute for Gene Therapy (SR-TIGET), IRCCS Ospedale San Raffaele, Milano

Da novembre 2014 a tutt’oggi: Project Leader, SR-TIGET, IRCCS Ospedale San Raffaele, Milano

Maggio 2010 - novembre 2014: Responsabile dell’Unità di Ricerca “Cellular Therapy” dei laboratori del Dipartimento di Ematologia ed Oncologia, IRCCS Ospedale Pediatrico Bambino Gesù, Roma.

Giugno 2004 - giugno 2005: fellowship presso il Dipartimento di Ematologia Sperimentale del Leiden University Medical Centre, sotto la supervisione del Prof. W.E. Fibbe, focalizzata sullo sviluppo di progetti di ricerca inerenti al trapianto allogenico di cellule staminali ematopoietiche in età pediatrica utilizzando le cellule stromali mesenchimali come supporto terapeutico

Membro del Board della European Hematology Association (EHA) (2017-2021)

Membro della Commissione Ricerca dell’EHA (2018-2021)   

Membro della Commissione “Grants and Fellowship” dell’EHA (2018-2021)

Direttore del Corso di Ricerca Clinica (Clinical Research Training in Hematology, CRTH) dell’EHA (2019-2020)

Da aprile 2020 a tutt’oggi: Co-Chair del Scientific Working Group di Ematologia Pediatrica dell’EHA.

Dal 2014 a tutt’oggi: revisore di abstract per il congresso annuale della Società Europea del Trapianto di Midollo Osseo (European Group for Blood and Marrow Transplantation, EBMT)

Dal 2017 a tutt’oggi: membro del Gruppo di Lavoro “Biologia Cellulare e Molecolare” della Società Italina di Ematologia ed Oncologia Pediatrica (AIEOP)

Dal 2016 a tutt’oggi: Editore Associato della rivista scientifica “Frontiers in Pediatrics, section Pediatric Hematology and Hematological Malignancies

2011-2014: Membro del Board Editoriale della rivista scientifica “Bone Marrow Transplantation”

Da gennaio 2020 a tutt’oggi: membro del “Data Safety Monitoring Board” (DSMB) per lo studio clinico di fase I/II sulla terapia genica ex-vivo con cellule staminali ematopoietiche nella Mucopolisaccaridosi di tipo IIIA, condotto presso l’Università di Manchester

Investigatore in numerosi studi clinici nazionali ed internazionali sul trapianto allogenico di cellule staminali ematopoietiche (HSCT) in pazienti pediatrici (identificazione della strategia ottimale per prevenire la malattia del trapianto contro l’ospite, GvHD, dopo HSCT allogenico; identificazione di schemi di chemioterapia di preparazione al trapianto caratterizzati da ridotta tossicità; approcci di terapia cellulare basati sull’utilizzo di cellule stromali mesenchimali durante e dopo l’HSCT allogenico)

Investigatore in studi clinici di terapia genica ex-vivo con cellule staminali ematopoietiche in pazienti pediatrici affetti da ADA-SCID, Sindrome di Wiskott-Aldrich, Leucodistrofia Metacromatica, Beta-Talassemia Major

Revisore per le riviste scientifiche: Blood, Haematologica, PlosOne, Cytotherapy, Cancer Research, Biology of Blood and Marrow Transplantation, Journal of Translational Medicine, Stem Cell and Development, Stem Cell Reports

Co-autore di > 100 lavori scientifici pubblicati su riviste internazionali e di N. 3 capitoli di libri. Parametri quantitativi della produzione scientifica in riviste scientifiche internazionali: indice h (Scopus) = 36; citazioni totali (Scopus) = >8000 (8207).

 

ALTRE INFORMAZIONI

Progetti di ricerca finanziati o in corso di finanziamento

Fondazione Telethon, SR-Tiget Core Grant (2016-2021). Investigatore Principale del progetto E6 “Use of mesenchimal stromal cells to optimize transplantation outcome of gene edited hematopoietic stem cells”.

Ha ricevuto un “Investigator Grant” (IG9062) dall’Associazione Italiana Ricerca sul Cancro (AIRC) nel 2009, intitolato Role of human mesenchymal stem cells in tumor angiogenesis”.

Ha ricevuto un finanziamento dal Ministero della Salute, Bando Giovani Ricercatori 2008 intitolato: “Mesenchymal stem cells and cancer: toward safer cell-based therapeutic application”.

Collaboratore (Investigator) in progetti di ricerca nazionali ed internazionali, incluso un progetto finanziato dalla Comunità Europea 6th Framework Program project Allostem (2004-2008, intitolato: “The development of immunotherapeutic strategies to treat hematological and neoplastic diseases on the basis of optimised allogeneic stem cell transplantation”). Collaboratore nel progetto finanziato dalla Comunità Europea bando HO2020: “RETHRIM” (#643580; intitolato: “Regeneration Through Immune Modulation”)

 

Membership di Società Scientifiche Nazionali ed Internazionali

Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)

European Hematology Association (EHA)

European Group for Blood and Marrow Transplantation (EBMT)

European Society of Gene and Cell Therapy (ESGCT)

Society for the Study of Inborn Errors of Metabolism (SSIEM)

 

Inviti a tenere letture a congressi nazionali ed internazionali (2017-2020)

46th Annual Meeting of the European Society for Blood and Marrow Transplantation. 30 agosto- 2 settembre 2020. Virtuale.

1st Midterm Focus Meeting on Non-Malignant Diseases of the EBMT. 8-10 luglio 2020. Virtuale.

23rd Annual Meeting of American Society for Gene and Cell Therapy (ASGCT). 13-15 maggio 2020. Boston, US. Virtuale.

24th Annual Meeting of European Hematology Association (EHA); Scientific Working Group on Mesenchymal Stromal Cells. 13-16 giugno 2019. Amsterdam, The Netherlands

EBMT Inborn Errors Working Party Conference. 28-30 Settembre 2019. Londra, UK

EBMT Inborn Errors Working Party Conference. 28-30 Settembre 2018. Leiden, NL

11th PDWP, IDWP, IEWP and Pediatric Nurse Group Meeting – Verona, 7-8 giugno 2018

44th Annual Meeting of the European Society for Blood and Marrow Transplantation. 24-27 marzo 2017. Francoforte, Germany

36th National Pediatric Meeting "Dercevi dnevi", Lubiana, 1 giugno 2018

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy. 23-25 novembre 2017. Amsterdam, The Netherlands

EBMT Inborn Errors Working Party Conference. 3-5 novembre 2017. Newcastle, UK

Advanced Therapies in Healthcare Conference. 27-29 ottobre 2017. Doha, Qatar

2017 MPS Symposium. 10-11 luglio 2017. Philadelphia, USA

Therapeutic Tolerance Workshop. 27-30 giugno 2017. Newcastle, UK

Transplantation in Inherited Metabolic Disease Course. Recordati Foundation. 8-10 giugno 2017. Lille, Francia

II Evento Nazionale sulle Mucopolisaccaridosi. 8-9 maggio 2017. Milano, Italia

43th Annual Meeting of the European Society for Blood and Marrow Transplantation. 26-29 marzo 2017. Marsiglia, France

Pubblicazioni

Full list of publications on international Journals

  1. Wolfs TFW, Attarbaschi A, Balduzzi A, Bernardo ME, Bomken S, Borkhardt A, Bourquin JP, Dufour C, Gennery A, Grainger J, Hasle H, Hrusak O, Izraeli S, Mechinaud F, Trka J, Vormoor. COVID-19 - Impact on Childhood Haematology Patients. Hemasphere. 2020 Sep 11;4(5):e465. doi: 10.1097/HS9.0000000000000465.
  2. Cenciarelli S, Calbi V, Barzaghi F, Bernardo ME, Oltolini C, Migliavacca M, Gallo V, Tucci F, Fraschetta F, Albertazzi E, Fratini ES, Consiglieri G, Giannelli S, Dionisio F, Sartirana C, Racca S, Camesasca C, Peretto G, Daverio R, Esposito A, De Cobelli F, Silvani P, Rabusin M, Cara A, Trabattoni D, Dispinseri S, Scarlatti G, Piemonti L, Lampasona V, Cicalese MP, Aiuti A, Ferrua F.Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. Front Immunol. 2020 Nov 24;11:603428. doi: 10.3389/fimmu.2020.603428.
  3. Tucci F, Gallo V, Barzaghi F, Ferrua F, Migliavacca M, Calbi V, Doglio M, Fratini ES, Karakas Z, Guner S, Zambelli M, Parisi C, Milani R, Gattillo S, Mazzi B, Oltolini C, Barbera M, Baldoli C, Cirillo DM, Asnaghi V, De Min C, Cicalese MP, Ciceri F, Aiuti A, Bernardo ME. Treatment with emapalumab in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated BCGitis. Haematologica. 2020 Aug 13:haematol.2020.255620. doi: 10.3324/haematol.2020.255620. IF: 7.11.
  4. Crippa S, Santi L, Bosotti R, Porro G, Bernardo ME. Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders. J Clin Med. 2019 Dec 18;9(1):2. IF: 3.3.
  5. Tucci F, Frittoli M, Barzaghi F, Calbi V, Migliavacca M, Ferrua F, Fumagalli F, Lorioli L, Castagnaro L, Facchini M, Fossati C, Zancan S, Massariello P, Manfredini M, Consiglieri G, Canarutto D, Recupero S, Calzatini F, Casiraghi M, Darin S, Antonioli G, Miniero R, Fiori R, Silvani P, Zambelli M, Marktel S, Gattillo S, Milani R, Santoleri L, Ciceri F, Biffi A, Cicalese MP, Bernardo ME, Aiuti A. Bone marrow harvesting from paediatric patients undergoing haematopoietic stem cell gene therapy. Bone Marrow Transplant. 2019 Dec;54(12):1995-2003. IF: 4.67
  6. Squeri G, Passerini L, Ferro F, Laudisa C, Tomasoni D, Deodato F, Donati MA, Gasperini S, Aiuti A, Bernardo ME, Gentner B, Naldini L, Annoni A, Biffi A, Gregori S. Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease. Mol Ther. 2019 Jul 3;27(7):1215-1227. IF: 8.40
  7. Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, Migliavacca M, Bernardo ME, Calbi V, Assanelli AA, Facchini M, Fossati C, Albertazzi E, Scaramuzza S, Brigida I, Scala S, Basso-Ricci L, Pajno R, Casiraghi M, Canarutto D, Salerio FA, Albert MH, Bartoli A, Wolf HM, Fiori R, Silvani P, Gattillo S, Villa A, Biasco L, Dott C, Culme-Seymour EJ, van Rossem K, Atkinson G, Valsecchi MG, Roncarolo MG, Ciceri F, Naldini L, Aiuti A. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematol. 2019 May;6(5):e239-e253. IF: 10.69
  8. Sereni L, Castiello MC, Di Silvestre D, Della Valle P, Brombin C, Ferrua F, Cicalese MP, Pozzi L, Migliavacca M, Bernardo ME, Pignata C, Farah R, Notarangelo LD, Marcus N, Cattaneo L, Spinelli M, Giannelli S, Bosticardo M, van Rossem K, D'Angelo A, Aiuti A, Mauri P, Villa A. Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2019 Sep;144(3):825-838. IF (2017): 13.25
  9. Crippa S, Rossella V, Aprile A, Silvestri L, Rivis S, Scaramuzza S, Pirroni S, Avanzini MA, Basso-Ricci L, Hernandez RJ, Zecca M, Marktel S, Ciceri F, Aiuti A, Ferrari G, Bernardo ME. Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity. J Clin Invest. 2019 Feb 25;129(4):1566-1580. IF: 13.25.
  10. Gnani D, Crippa S, Della Volpe L, Rossella V, Conti A, Lettera E, Rivis S, Ometti M, Fraschini G, Bernardo ME, Di Micco R. An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program. Aging Cell. 2019 Jun;18(3):e12933. IF: 7.34
  11. Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, Yabe H, Chinen Y, Boelens JJ, Mason RW, Kubaski F, Horovitz DDG, Barth AL, Serafini M, Bernardo ME, Kobayashi H, Orii KE, Suzuki Y, Orii T, Tomatsu S. Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. Biol Blood Marrow Transplant. 2019 Jul;25(7):e226-e246. IF: 4.48
  12. Marktel S, Scaramuzza S, Cicalese MP, Giglio F, Galimberti S, Lidonnici MR, Calbi V, Assanelli A, Bernardo ME, Rossi C, Calabria A, Milani R, Gattillo S, Benedicenti F, Spinozzi G, Aprile A, Bergami A, Casiraghi M, Consiglieri G, Masera N, D'Angelo E, Mirra N, Origa R, Tartaglione I, Perrotta S, Winter R, Coppola M, Viarengo G, Santoleri L, Graziadei G, Gabaldo M, Valsecchi MG, Montini E, Naldini L, Cappellini MD, Ciceri F, Aiuti A, Ferrari G. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. Nat Med. 2019 Feb;25(2):234-241. IF: 32.62
  13. Crippa S, Bernardo ME. Mesenchymal Stromal Cells: Role in the BM Niche and in the Support of Hematopoietic Stem Cell Transplantation. Hemasphere. 2018 Nov 16;2(6):e151.
  14. Fraldi A, Serafini M, Sorrentino NC, Gentner B, Aiuti A, Bernardo ME. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Ital J Pediatr. 2018 Nov 16;44(Suppl 2):130. IF: 1.77
  15. Gruarin P, Maglie S, De Simone M, Häringer B, Vasco C, Ranzani V, Bosotti R, Noddings JS, Larghi P, Facciotti F, Sarnicola ML, Martinovic M, Crosti M, Moro M, Rossi RL, Bernardo ME, Caprioli F, Locatelli F, Rossetti G, Abrignani S, Pagani M, Geginat J. Eomesodermin controls a unique differentiation program in human IL-10 and IFN-γ coproducing regulatory T cells. Eur J Immunol. 2019 Jan;49(1):96-111. IF: 4.24
  16. Trento C,* Bernardo ME,* Nagler A, Kuçi S, Bornhäuser M, Köhl U, Strunk D, Galleu A, Sanchez-Guijo F, Gaipa G, Introna M, Bukauskas A, Le Blanc K, Apperley J, Roelofs H, Van Campenhout A, Beguin Y, Kuball J, Lazzari L, Avanzini MA, Fibbe W, Chabannon C, Bonini C, Dazzi F. Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 Nov;24(11):2365-2370. IF: 4.48.
  17. Tucci T, Calbi V, Barzaghi F, Migliavacca M, Ferrua, Bernardo ME, Canarutto D, Consiglieri G, Recupero S, Calzatini F, Gabaldo M, Lucano C, Casiraghi M, Darin S, Dionisio F, Marktel S, Cestone E, Finazzi R, Mieli-Vergani G, Boeri E, Aplleby J, Abd Elaziz D, Ciceri F, Aiuti A, Cicalese MP. Successful treatment with Harvoni® in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis. Hepatology 2018 Dec; 68(6):2434-2437. IF (2017): 14.07.
  18. Calbi V, Fumagalli F, Consiglieri G, Penati R, Acquati S, Redaelli D, Attanasio V, Marcella F, Cicalese MP, Migliavacca M, Barzaghi F, Ferrua F, Assanelli A, Silvani P, Zoccolillo M, Chidini G, Chiesa R, Arora R, Ciotti F, Sarzana M, Antonioli G, Baldoli C, Morena F, Martino S, Ardissino GL, Sora MGN, Naldini L, Ciceri F, Aiuti A, Bernardo ME. Use of Defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy. Bone Marrow Transplant. 2018 Jul;53(7):913-917. IF: 4.67
  19. Starc N, Li M, Algeri M, Conforti A, Tomao L, Pitisci A, Emma F, Montini G, Messa P, Locatelli F, Bernardo ME,* Vivarelli M.* Phenotypic and functional characterization of mesenchymal stromal cells isolated from pediatric patients with severe idiopathic nephrotic syndrome. Cytotherapy 2018 Mar;20(3):322-334. IF: 3.20
  20. Gualerzi A, Niada S, Giannasi C, Picciolini S, Morasso C, Vanna R, Rossella V, Masserini M, Bedoni M, Ciceri F, Bernardo ME, Brini AT, Gramatica F. Raman spectroscopy uncovers biochemical tissue-related features of extracellular vesicles from mesenchymal stromal cells. Sci Rep. 2017 Aug 29;7(1):98 IF: 4.25
  21. Azario I, Pievani A, Del Priore F, Antolini L, Santi L, Corsi A, Cardinale L, Sawamoto K, Kubaski F, Gentner B, Bernardo ME, Valsecchi MG, Riminucci M, Tomatsu S, Aiuti A, Biondi A, Serafini M. Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I. Sci Rep. 2017 Aug 25;7(1):9473. IF: 4.25
  22. Starc N, Ingo D, Conforti C, Rossella V, Tomao L, Pitisci A, De Mattia F, Brigida I, Algeri M, Montanari M, Palumbo G, Merli P, Rossi P, Aiuti A, Locatelli F, Bernardo ME. Biological and functional characterization of bone marrow-derived mesenchymal stromal cells from patients affected by primary immunodeficiency. Sci Rep. 2017 Aug 15;7(1):8153. IF: 4.12
  23. Locatelli F, Bernardo ME, Bertaina A, Rognoni C, Comoli P, Rovelli A, Pession A, Fagioli F, Favre C, Lanino E, Giorgiani G, Merli P, Pagliara D, Prete A, Zecca M. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1126-1136. IF: 36.42
  24. Penati R, Fumagalli F, Calbi V, Bernardo ME, Aiuti A. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis. 2017 Jul;40(4):543-554. IF: 3.97
  25. Basso-Ricci L, Scala S, Milani R, Migliavacca M, Rovelli A, Bernardo ME, Ciceri F, Aiuti A, Biasco L. Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system. Cytometry A. 2017 Oct;91(10):952-965. IF: 3.22
  26. Ingo DM, Redaelli D, Rossella V, Perini O, Santoleri L, Ciceri F, Aiuti A, Bernardo ME. Bone marrow-derived CD34(-) fraction: A rich source of mesenchymal stromal cells for clinical application. Cytotherapy. 2016 Dec;18(12):1560-1563. IF: 3.20
  27. Montagna M, La Nasa G, Bernardo ME, Piras E, Avanzini MA, Regazzi M, Locatelli F. A New Enzyme-Linked Immunosorbent Assay for a Total Anti-T Lymphocyte Globulin Determination: Development, Analytical Validation, and Clinical Applications. Ther Drug Monit. 2017 Jun;39(3):282-289. IF: 2.17
  28. Conforti A, Starc N, Biagini S, Tomao L, Pitisci A, Algeri M, Sirleto P, Novelli A, Grisendi G, Candini O, Carella C, Dominici M, Locatelli F, Bernardo ME. Resistance to neoplastic transformation of ex-vivo expanded human mesenchymal stromal cells after exposure to supramaximal physical and chemical stress. Oncotarget. 2016 Nov 22;7(47):77416-77429. IF: 5.16
  29. Bernardo ME, Aiuti A. The role of conditioning in hematopoietic stem cell gene therapy. Hum Gene Ther. 2016 Oct;27(10):741-748. IF: 4.18
  30. Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, Gibson B, Sedlacek P, Krol L, Strahm B, Zaidman I, Kalwak K, Talano JA, Woolfrey A, Fraser C, Meyts I, Müller I, Wachowiak J, Bernardo ME, Veys P, Sykora KW, Gennery AR, Slatter M. Treosulfan-based conditioning for allogeneic HSCT in children withchronic granulomatous disease: a multicenter experience. Blood. 2016 Jul 21;128(3):440-8. IF: 13.16
  31. Rossi F, Bellini G, Luongo L, Manzo I, Tolone S, Tortora C, Bernardo ME, Grandone A, Conforti A, Docimo L, Nobili B, Perrone L, Locatelli F, Maione S, Del Giudice EM. Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation. J Clin Endocrinol Metab. 2016 Sep;101(9):3469-78. IF: 5.45
  32. Migliavacca M, Assanelli A, Ferrua F, Cicalese MP, Biffi A, Frittoli M,Silvani P, Chidini G, Calderini E, Mandelli A, Camporesi A, Milani R, Farinelli G, Nicoletti R, Ciceri F, Aiuti A, Bernardo ME. Pioglitazone as a novel therapeutic approach in chronic granulomatous disease. J Allergy Clin Immunol. 2016 Jun;137(6):1913-1915.e2. IF: 13.08
  33. Ciccocioppo R, Cangemi GC, Kruzliak P, Gallia A, Betti E, Badulli C, Martinetti M, Cervio M, Pecci A, Bozzi V, Dionigi P, Visai L, Gurrado A, Alvisi C, Picone C, Monti M, Bernardo ME, Gobbi P, Corazza GR. Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact. Stem Cell Res Ther. 2015 Jul 24;6:137. IF: 1.97
  34. Algeri M, Conforti A, Pitisci A, Starc N, Tomao L, Bernardo ME, Locatelli F. Mesenchymal stromal cells and chronic inflammatory bowel disease. Immunol Lett. 2015;168(2):191-200. IF: 2.48
  35. Rossi F, Bellini G, Tortora C, Bernardo ME, Luongo L, Conforti A, Starc N, Manzo I, Nobili B, Locatelli F, Maione S. CB(2) and TRPV(1) receptors oppositely modulate in vitro human osteoblast activity. Pharmacol Res. 2015;99:194-201. IF: 4.81
  36. Bernardo ME, Fibbe WE. Mesenchymal stromal cells and hematopoietic stem cell transplantation. Immunol Lett. 2015;168:215-21. IF: 2.48
  37. Mantelli M, Avanzini MA, Rosti V, Ingo DM, Conforti A, Novara F, Arrigo G, Boni M, Zappatore R, Lenta E, Moretta A, Acquafredda G, de Silvestri A, Cirillo V, Cicchetti E, Algeri M, Strocchio L, Vinti L, Starc N, Biagini S, Sirleto P, Bernasconi P, Zuffardi O, Maserati E, Maccario R, Zecca M, Locatelli F, Bernardo ME. Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. Br J Haematol. 2015;170:826-36. IF: 5.81
  38. Airoldi I, Bertaina A, Prigione I, Zorzoli A, Pagliara D, Cocco C, Meazza R, Loiacono F, Lucarelli B, Bernardo ME, Barbarito G, Pende D, Moretta A, Pistoia V, Moretta L, Locatelli F. γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes. Blood. 2015;125:2349-58. IF: 11.84
  39. Conforti A, Taranta A, Biagini S, Starc N, Pitisci A, Bellomo F, Cirillo V, Locatelli F, Bernardo ME, Emma F. Cysteamine treatment restores the in vitro ability to differentiate along the osteoblastic lineage of mesenchymal stromal cells isolated from bone marrow of a cystinotic patient. J Transl Med. 2015; 7:143. IF: 3.69
  40. Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G, Pessina A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014 Oct 28;192:262-70. IF: 7.70
  41. Rosado MM, Bernardo ME, Scarsella M, Conforti A, Giorda E, Biagini S, Cascioli S, Rossi F, Guzzo I, Vivarelli M, Dello Strologo L, Emma F, Locatelli F, Carsetti R. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev. 2015 Jan 1;24(1):93-103. IF: 3.77
  42. Conforti A, Scarsella M, Starc N, Giorda E, Biagini S, Proia A, Carsetti R, Locatelli F, Bernardo ME. Microvesicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev. 2014; 23:2591-9. IF: 3.72
  43. Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, Pende D, Falco M, Handgretinger R, Moretta F, Lucarelli B, Brescia LP, Li Pira G, Testi M, Cancrini C, Kabbara N, Carsetti R, Finocchi A, Moretta A, Moretta L, Locatelli F. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B-cells in children with non-malignant disorders. Blood. 2014 Jul 31;124(5):822-6. IF: 10.45
  44. Conforti A, Biagini S, Starc N, Proia A, Pessina A, Alessandri G, Locatelli F, Bernardo ME. Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro. Cytotherapy. 2014 Jun;16(6):868-70. IF: 3.29
  45. Avanzini MA, Bernardo ME, Novara F, Mantelli M, Poletto V, Villani L, Lenta E, Ingo DM, Achille V, Bonetti E, Massa M, Campanelli R, Fois G, Catarsi P, Gale RP, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V. Functional and genetic aberrations of in vitro cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. Leukemia. 2014 Aug;28(8):1742-5. IF: 10.43
  46. Rossi F, Bernardo ME, Bellini G, Luongo L, Conforti A, Manzo I, Guida F, Cristino L, Imperatore R, Petrosino S, Nobili B, Di Marzo V, Locatelli F, Maione S. The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties. PLoS One. 2013 Nov 27;8(11):e80022. IF: 3.53
  47. Conforti A, Biagini S, Del Bufalo F, Sirleto P, Angioni A, Starc N, Li Pira G, Moretta F, Proia A, Contoli B, Genovese S, Ciardi C, Avanzini MA, Rosti V, Lo-Coco F, Locatelli F, Bernardo ME. Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemia. PLoS One. 2013 Nov 7;8(11):e76989. IF: 3.53
  48. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013 Oct 3;13(4):392-402. IF: 22.15
  49. Ball LM,* Bernardo ME,* Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, Avanzini MA, Conforti A, Bertaina A, Giorgiani G, Jol-van der Zijde CM, Zecca M, Le Blanc K, Frassoni F, Egeler RM, Fibbe WE, Lankester AC, Locatelli F. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013 Nov;163(4):501-9. IF: 4.95 (Corresponding)
  50. Ciccocioppo R, Russo ML, Bernardo ME, Biagi F, Catenacci L, Avanzini MA, Alvisi C, Vanoli A, Manca R, Luinetti O, Locatelli F, Corazza GR. Mesenchymal stromal cell infusions as rescue therapy for corticosteroid-refractory adult autoimmune enteropathy. Mayo Clin Proc. 2012 Sep;87(9):909-14. IF (2014): 6.68
  51. Marletta C, Valli R, Pressato B, Mare L, Montalbano G, Menna G, Loffredo G, Bernardo ME, Vinti L, Ferrari S, Di Cesare-Merlone A, Zecca M, Lo Curto F, Locatelli F, Pasquali F, Maserati E. Chromosome anomalies in bone marrow as primary cause of aplastic or hypoplastic conditions and peripheral cytopenia: disorders due to secondary impairment of RUNX1 and MPL genes. Mol Cytogenet. 2012 Oct 1;5(1):39. IF: 2.36
  52. de Girolamo L, Lucarelli E, Alessandri G, Avanzini MA, Bernardo ME, Biagi E, Brini AT, D'Amico G, Fagioli F, Ferrero I, Locatelli F, Maccario R, Marazzi M, Parolini O, Pessina A, Torre ML, Italian Mesenchymal Stem Cell Group. Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy. Curr Pharm Des. 2013;19(13):2459-73. IF: 3.28
  53. Ciccocioppo R, Bernardo ME, Russo ML, Vanoli A, Franco C, Martinetti M, Catenacci L, Giorgiani G, Zecca M, Piralla A, Baldanti F, Locatelli F, Corazza GR. Allogeneic hematopoietic stem cell transplantation may restore gluten tolerance in patients with celiac disease. J Pediatr Gastroenterol Nutr. 2013 Apr;56(4):422-7. IF: 2.87
  54. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci. 2012 Aug;1266:107-17. IF: 4.36
  55. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2807-16. IF: 9.06
  56. Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, Pagliara D, Contoli B, Pinto RM, Caocci G, Mastronuzzi A, La Nasa G, Locatelli F. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012 Jul 12;120(2):473-6. IF: 9.06
  57. Clave E, Lisini D, Douay C, Giorgiani G, Busson M, Zecca M, Charron D, Bernardo ME, Toubert A, Locatelli F. A low thymic function is associated with leukemia relapse in children given T-cell-depleted HLA-haploidentical stem cell transplantation. Leukemia. 2012 Aug;26(8):1886-8. IF: 10.16
  58. Daniele N, Scerpa MC, Caniglia M, Ciammetti C, Rossi C, Bernardo ME, Locatelli F, Isacchi G, Zinno F. Overview of T-cell depletion in haploidentical stem cell transplantation. Blood Transfus. 2012 Jul;10(3):264-72. IF: 1.85
  59. Daniele N, Scerpa MC, Caniglia M, Bernardo ME, Rossi C, Ciammetti C, Palumbo G, Locatelli F, Isacchi G, Zinno F. Transplantation in the onco-hematology field: focus on the manipulation of αβ and γδ T cells. Pathol Res Pract. 2012 Feb 15;208(2):67-73. IF: 1.21
  60. Locatelli F, Vinti L, Palumbo G, Rossi F, Bertaina A, Mastronuzzi A, Bernardo ME, Rutella S, Dellabona P, Giorgiani G, Moretta A, Moretta L. Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2011 Sep;24(3):339-49. IF: 2.63
  61. Bernardo ME, Cometa AM, Locatelli F. Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation? Bone Marrow Transplant. 2012 Mar;47(3):323-9. IF: 3.54
  62. Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? Bone Marrow Transplant. 2012 Feb;47(2):164-71. IF: 3.54
  63. Achille V, Mantelli M, Arrigo G, Novara F, Avanzini MA, Bernardo ME, Zuffardi O, Barosi G, Zecca M, Maccario R. Cell-cycle phases and genetic profile of bone marrow-derived mesenchymal stromal cells expanded in vitro from healthy donors. J Cell Biochem. 2011 Jul;112(7):1817-21. IF: 2.86
  64. Bernardo ME, Cometa AM, Pagliara D, Vinti L, Rossi F, Cristantielli R, Palumbo G, Locatelli F. Ex vivo expansion of mesenchymal stromal cells. Best Pract Res Clin Haematol. 2011 Mar;24(1):73-81. IF: 2.63
  65. Comite P, Cobianchi L, Avanzini MA, Mantelli M, Achille V, Zonta S, Ferrari C, Alessiani M, De Silvestri A, Gandolfo GM, Inverardi L, Brescia L, Pietrabissa A, Dionigi P, Locatelli F, Bernardo ME. Immunomodulatory properties of porcine, bone marrow-derived multipotent mesenchymal stromal cells and comparison with their human counterpart. Cell Mol Biol (Noisy-le-grand). 2011 Oct 15;57 Suppl:OL1600-5. IF: 0.97
  66. de Lalla C, Rinaldi A, Montagna D, Azzimonti L, Bernardo ME, Sangalli LM, Paganoni AM, Maccario R, Di Cesare-Merlone A, Zecca M, Locatelli F, Dellabona P, Casorati G. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4-subset dynamics and correlates with remission state. J Immunol. 2011 Apr 1;186(7):4490-9. IF: 5.78
  67. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011 Jun;60(6):788-98. IF: 10.11
  68. Bertaina A, Bernardo ME, Caniglia M, Vinti L, Giorgiani G, Locatelli F. Cord blood transplantation in children with haematological malignancies. Best Pract Res Clin Haematol. 2010 Jun;23(2):189-96. IF: 2.17
  69. Bertaina A, Bernardo ME, Mastronuzzi A, La Nasa G, Locatelli F. The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation. Ann N Y Acad Sci. 2010 Aug;1202:141-8. IF: 2.84
  70. Comite P, Cobianchi L, Avanzini MA, Zonta S, Mantelli M, Achille V, De Martino M, Cansolino L, Ferrari C, Alessiani M, Maccario R, Gandolfo GM, Dionigi P, Locatelli F, Bernardo ME. Isolation and ex vivo expansion of bone marrow-derived porcine mesenchymal stromal cells: potential for application in an experimental model of solid organ transplantation in large animals. Transplant Proc. 2010 May;42(4):1341-3. IF: 0.99
  71. Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V. Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia. 2010 Jul;24(7):1368-70. IF: 8.96
  72. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, Bertaina A, Vinti L, Lankester A, Maccario R, Ringden O, Le Blanc K, Egeler RM, Fibbe WE, Locatelli F. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2011 Feb;46(2):200-7. IF: 3.74
  73. Bernardo ME, Avanzini MA, Ciccocioppo R, Perotti C, Cometa AM, Moretta A, Marconi M, Valli M, Novara F, Bonetti F, Zuffardi O, Maccario R, Corazza GR, Locatelli F. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy. 2009;11(7):825-36. IF: 2.20
  74. Avanzini MA, Bernardo ME,§ Cometa AM, Perotti C, Zaffaroni N, Novara F, Visai L, Moretta A, Del Fante C, Villa R, Ball LM, Fibbe WE, Maccario R, Locatelli F. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica. 2009 Dec;94(12):1649-60. IF: 6.41
  75. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci. 2009 Sep;1176:101-17. IF: 2.67
  76. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009 Mar 26;113(13):3119-29. IF: 10.55
  77. Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, Pession A, Giraldi E, Parasole R, Barberi W, Zecca M. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol. 2009 Nov;147(3):371-8. IF: 4.59
  78. Pessina A, Bonomi A, Coccè V, Bernardo ME, Cometa AM, Ferrari M, Sisto F, Cavicchini L, Locatelli F. Assessment of human herpesvirus-6 infection in mesenchymal stromal cells ex vivo expanded for clinical use. Transpl Infect Dis. 2009 Dec;11(6):491-6. IF: 2.06
  79. Novara F, Beri S, Bernardo ME, Bellazzi R, Malovini A, Ciccone R, Cometa AM, Locatelli F, Giorda R, Zuffardi O. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 2009 Oct;126(4):511-20. IF: 4.52
  80. Ball LM, Bernardo ME, Locatelli F, Egeler RM. Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT. Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S60-6. IF: 3.40
  81. Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, Caocci G, Comoli P, Mastronuzzi A, Merli P, La Nasa G, Locatelli F. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008 Nov;143(4):548-51. IF: 4.47
  82. Comoli P, Schilham MW, Basso S, van Vreeswijk T, Bernardo ME, Maccario R, van Tol MJ, Locatelli F, Veltrop-Duits LA. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother. 2008 Jul-Aug;31(6):529-36. IF: 3.66
  83. Beluffi G, Bernardo ME, Meloni G, Spinazzola A, Locatelli F. Spinal osteomyelitis due to Aspergillus flavus in a child: a rare complication after haematopoietic stem cell transplantation. Pediatr Radiol. 2008 Jun;38(6):709-12. IF: 1.18
  84. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, Locatelli F, Aversa F, Velardi A. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood. 2008 Oct 1;112(7):2990-5. IF: 10.43
  85. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008 May 10;371(9624):1579-86. IF: 28.40
  86. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007 Oct 1;67(19):9142-9. IF: 7.67
  87. Perotti G, Bernardo ME, Spalla M, Matti C, Stronati M, Pagani L. Rapid control of two outbreaks of Serratia marcescens in a Northern Italian neonatal intensive care unit. J Chemother. 2007 Oct;19 Suppl 2:56-60. IF: 0.92
  88. Ball LM,* Bernardo ME,* Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007 Oct 1;110(7):2764-7. IF: 10.89
  89. Locatelli F, Zecca M, Pession A, Morreale G, Longoni D, Di Bartolomeo P, Porta F, Fagioli F, Nobili B, Bernardo ME, Messina C; Italian pediatric group. The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group. Haematologica. 2007 Oct;92(10):1381-8. IF: 5.51
  90. La Nasa G, Littera R, Locatelli F, Lai S, Alba F, Caocci G, Lisini D, Nesci S, Vacca A, Piras E, Bernardo ME, Di Cesare-Merlone A, Orrù S, Carcassi C. The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia. Br J Haematol. 2007 Oct;139(2):284-8. IF: 4.49
  91. Lilleri D, Gerna G, Furione M, Bernardo ME, Giorgiani G, Telli S, Baldanti F, Locatelli F. Use of a DNAemia cut-off for monitoring human citomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood. 2007 Oct 1;110(7):2757-60. IF: 10.89
  92. Bernardo ME, Emons JA, Karperien M, Nauta AJ, Willemze R, Roelofs H, Romeo S, Marchini A, Rappold GA, Vukicevic S, Locatelli F, Fibbe WE. Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res. 2007;48(3):132-40. IF: 1.08
  93. Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del Fante C, Novara F, de Silvestri A, Amendola G, Zuffardi O, Maccario R, Locatelli F. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol. 2007 Apr;211(1):121-30. IF: 3.64
  94. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007 Jun;7(6):1648-55. IF: 6.42
  95. Porta G, Maserati E, Mattarucchi E, Minelli A, Pressato B, Valli R, Zecca M, Bernardo ME, Lo Curto F, Locatelli F, Danesino C, Pasquali F. Monosomy 7 in myeloid malignancies: parental origin and monitoring by real-time quantitative PCR. Leukemia. 2007 Aug;21(8):1833-5. IF: 6.92
  96. Avanzini MA, Maccario R, Locatelli F, Giebel S, Santos CD, Bernardo ME, Pagliara D, Montagna D, Longo S, Amendola G, Marconi M. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stemcell transplantation. Exp Hematol. 2006 Oct;34(10):1429-34. IF: 3.40
  97. Montagna D, Daudt L, Locatelli F, Montini E, Turin I, Lisini D, Giorgiani G, Bernardo ME, Maccario R. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction. Cancer Res. 2006 Jul 15;66(14):7310-6. IF: 7.65
  98. Pozzi S, Lisini D, Podestà M, Bernardo ME, Sessarego N, Piaggio G, Cometa A, Giorgiani G, Mina T, Buldini B, Maccario R, Frassoni F, Locatelli F. Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Exp Hematol. 2006 Jul;34(7):934-42. IF: 3.40
  99. Minelli A, Maserati E, Rossi G, Bernardo ME, De Stefano P, Cecchini MP, Valli R, Albano V, Pierani P, Leszl A, Sainati L, Lo Curto F, Danesino C, Locatelli F, Pasquali F. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies. Genes Chromosomes Cancer. 2004 Jul;40(3):165-71. IF: 4.27
  100. Maserati E, Minelli A, Menna G, Cecchini MP, Bernardo ME, Rossi G, De Filippi P, Lo Curto F, Danesino C, Locatelli F, Pasquali F. Familial myelodysplastic syndromes, monosomy 7/trisomy 8, and mutator effects. Cancer Genet Cytogenet. 2004 Jan 15;148(2):155-8. IF: 1.57
  101. Locatelli F, Giorgiani G, Giraldi E, Castelnovi C, Stroppa P, Bernardo ME, Bonetti F, Maccario R. Cord blood transplantation in childhood. Haematologica. 2000 Nov; 85 (11 Suppl):26-9. IF: 2.53

* co-first

 

§ corresponding author

 

 

Book chapters

 

Bernardo ME, Locatelli F. Mesenchymal Stromal Cells in Hematopoietic Stem Cell Transplantation. Methods Mol Biol. 2016;1416:3-20.

 

Locatelli F, Bernardo ME. HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH THALASSEMIA. In: “The handbook. Disorders of iron homeostasis, erithrocytes, erythropoiesis”. European School of Hematology. Forum Service Ed. 2008.

 

Locatelli F, Bernardo ME. HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH THALASSEMIA. In: “The handbook. Disorders of iron homeostasis, erithrocytes, erythropoiesis”. European School of Hematology. Forum Service Ed. 2006.

 

 

Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.